BIOGEN INC. APIC, Share-based Payment Arrangement, Recognition and Exercise
BIOGEN INC. (BIIB) reported APIC, Share-based Payment Arrangement, Recognition and Exercise of $144.40 million for the 9-month period ending 2015-09-30, per its 10-Q filed 2015-10-21.
Discontinued › Notes › Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions · last filed 2015-10-21
- BIOGEN INC. apic, share-based payment arrangement, recognition and exercise for the quarter ending 2015-03-31 was $46.30M, a 48.87% increase year-over-year.
- BIOGEN INC. apic, share-based payment arrangement, recognition and exercise for the quarter ending 2014-09-30 was $44.00M, a 36.60% decline year-over-year.
- BIOGEN INC. apic, share-based payment arrangement, recognition and exercise for the quarter ending 2014-06-30 was $51.30M.
- BIOGEN INC. apic, share-based payment arrangement, recognition and exercise for the quarter ending 2014-03-31 was $31.10M.
| Period end | APIC, Share-based Payment Arrangement, Recognition and Exercise 3 month | APIC, Share-based Payment Arrangement, Recognition and Exercise 6 month | APIC, Share-based Payment Arrangement, Recognition and Exercise 9 month |
|---|---|---|---|
| 2015-09-30 | $144.40M 10-Q · filed 2015-10-21 | ||
| 2015-03-31 | $46.30M 10-Q · filed 2015-04-24 | ||
| 2014-09-30 | $44.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-10-22 | $95.30M derived: sum of 2 quarters · filed 2014-10-22 | $126.40M 10-Q · filed 2014-10-22 |
| 2014-06-30 | $51.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-07-23 | $82.40M 10-Q · filed 2014-07-23 | |
| 2014-03-31 | $31.10M 10-Q · filed 2014-04-23 | ||
| 2013-09-30 | $69.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-10-28 | $132.90M 10-Q · filed 2013-10-28 | |
| 2013-06-30 | $63.50M 10-Q · filed 2013-07-25 | ||
| 2012-09-30 | $46.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-10-25 | $101.80M derived: sum of 2 quarters · filed 2012-10-25 | $134.00M 10-Q · filed 2012-10-25 |
| 2012-06-30 | $55.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-07-24 | $87.40M 10-Q · filed 2012-07-24 | |
| 2012-03-31 | $32.20M 10-Q · filed 2012-05-01 | ||
| 2011-09-30 | $299.50M 10-Q · filed 2011-10-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |